C5b-9 and interleukin-6 in chronic hepatitis C: Surrogate markers predicting short-term response to interferon alpha-2b

L. Biro, L. Varga, A. Pár, E. Nemesanszky, L. Telegdy, E. Ibranyi, K. David, G. Horvath, L. Szentgyorgyi, I. Nagy, L. Dalmi, M. Abonyi, G. Füst, M. Horányi, A. Csepregi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Available data and our observations suggest that elevated levels of interleukin (IL)-6 and -10 and some complement parameters may be associated with a poor response to IFN alpha. We evaluated how baseline levels of C5b-9, IL-6, and IL-10 influence the outcome of IFN alpha treatment. Methods: Fifty-one patients with established chronic hepatitis C were enrolled and treated with IFN alpha-2b. Before and after a 12-week-IFN-treatment (3 MU or 5 MU tiw) serum levels of IL-6, IL-10, C5b-9 and RNA of hepatitis C virus (HCV) were assessed. Sera of 46 sex- and age-matched, healthy blood donors served as control. Results: While two-thirds of patients was considered 'responder', 14 patients had no significant decrease either in HCV RNA or in ALT levels. In the responder's group lower baseline levels of IL-6 and C5b-9 were found than those in the 'non-responder' group. As a result of IFN therapy HCV RNA and C5b-9 levels significantly decreased. While the serum concentration of IL-6 increased during the follow-up period, regarding IL-10, no change was observed. In patients with 'low' baseline levels of C5b-9 (

Original languageEnglish
Pages (from-to)1092-1096
Number of pages5
JournalScandinavian Journal of Gastroenterology
Volume35
Issue number10
Publication statusPublished - 2000

Fingerprint

interferon alfa-2b
Complement Membrane Attack Complex
Chronic Hepatitis C
Interleukin-6
Biomarkers
Interleukin-10
Hepacivirus
RNA
Serum
Blood Donors
Therapeutics

Keywords

  • C5b-9
  • Chronic hepatitis C
  • Interferon alpha-2b
  • Interleukin-6
  • Short-term response

ASJC Scopus subject areas

  • Gastroenterology

Cite this

C5b-9 and interleukin-6 in chronic hepatitis C : Surrogate markers predicting short-term response to interferon alpha-2b. / Biro, L.; Varga, L.; Pár, A.; Nemesanszky, E.; Telegdy, L.; Ibranyi, E.; David, K.; Horvath, G.; Szentgyorgyi, L.; Nagy, I.; Dalmi, L.; Abonyi, M.; Füst, G.; Horányi, M.; Csepregi, A.

In: Scandinavian Journal of Gastroenterology, Vol. 35, No. 10, 2000, p. 1092-1096.

Research output: Contribution to journalArticle

Biro, L, Varga, L, Pár, A, Nemesanszky, E, Telegdy, L, Ibranyi, E, David, K, Horvath, G, Szentgyorgyi, L, Nagy, I, Dalmi, L, Abonyi, M, Füst, G, Horányi, M & Csepregi, A 2000, 'C5b-9 and interleukin-6 in chronic hepatitis C: Surrogate markers predicting short-term response to interferon alpha-2b', Scandinavian Journal of Gastroenterology, vol. 35, no. 10, pp. 1092-1096.
Biro, L. ; Varga, L. ; Pár, A. ; Nemesanszky, E. ; Telegdy, L. ; Ibranyi, E. ; David, K. ; Horvath, G. ; Szentgyorgyi, L. ; Nagy, I. ; Dalmi, L. ; Abonyi, M. ; Füst, G. ; Horányi, M. ; Csepregi, A. / C5b-9 and interleukin-6 in chronic hepatitis C : Surrogate markers predicting short-term response to interferon alpha-2b. In: Scandinavian Journal of Gastroenterology. 2000 ; Vol. 35, No. 10. pp. 1092-1096.
@article{9c7a455e09604ab58d76c38bbad52e6d,
title = "C5b-9 and interleukin-6 in chronic hepatitis C: Surrogate markers predicting short-term response to interferon alpha-2b",
abstract = "Background: Available data and our observations suggest that elevated levels of interleukin (IL)-6 and -10 and some complement parameters may be associated with a poor response to IFN alpha. We evaluated how baseline levels of C5b-9, IL-6, and IL-10 influence the outcome of IFN alpha treatment. Methods: Fifty-one patients with established chronic hepatitis C were enrolled and treated with IFN alpha-2b. Before and after a 12-week-IFN-treatment (3 MU or 5 MU tiw) serum levels of IL-6, IL-10, C5b-9 and RNA of hepatitis C virus (HCV) were assessed. Sera of 46 sex- and age-matched, healthy blood donors served as control. Results: While two-thirds of patients was considered 'responder', 14 patients had no significant decrease either in HCV RNA or in ALT levels. In the responder's group lower baseline levels of IL-6 and C5b-9 were found than those in the 'non-responder' group. As a result of IFN therapy HCV RNA and C5b-9 levels significantly decreased. While the serum concentration of IL-6 increased during the follow-up period, regarding IL-10, no change was observed. In patients with 'low' baseline levels of C5b-9 (",
keywords = "C5b-9, Chronic hepatitis C, Interferon alpha-2b, Interleukin-6, Short-term response",
author = "L. Biro and L. Varga and A. P{\'a}r and E. Nemesanszky and L. Telegdy and E. Ibranyi and K. David and G. Horvath and L. Szentgyorgyi and I. Nagy and L. Dalmi and M. Abonyi and G. F{\"u}st and M. Hor{\'a}nyi and A. Csepregi",
year = "2000",
language = "English",
volume = "35",
pages = "1092--1096",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - C5b-9 and interleukin-6 in chronic hepatitis C

T2 - Surrogate markers predicting short-term response to interferon alpha-2b

AU - Biro, L.

AU - Varga, L.

AU - Pár, A.

AU - Nemesanszky, E.

AU - Telegdy, L.

AU - Ibranyi, E.

AU - David, K.

AU - Horvath, G.

AU - Szentgyorgyi, L.

AU - Nagy, I.

AU - Dalmi, L.

AU - Abonyi, M.

AU - Füst, G.

AU - Horányi, M.

AU - Csepregi, A.

PY - 2000

Y1 - 2000

N2 - Background: Available data and our observations suggest that elevated levels of interleukin (IL)-6 and -10 and some complement parameters may be associated with a poor response to IFN alpha. We evaluated how baseline levels of C5b-9, IL-6, and IL-10 influence the outcome of IFN alpha treatment. Methods: Fifty-one patients with established chronic hepatitis C were enrolled and treated with IFN alpha-2b. Before and after a 12-week-IFN-treatment (3 MU or 5 MU tiw) serum levels of IL-6, IL-10, C5b-9 and RNA of hepatitis C virus (HCV) were assessed. Sera of 46 sex- and age-matched, healthy blood donors served as control. Results: While two-thirds of patients was considered 'responder', 14 patients had no significant decrease either in HCV RNA or in ALT levels. In the responder's group lower baseline levels of IL-6 and C5b-9 were found than those in the 'non-responder' group. As a result of IFN therapy HCV RNA and C5b-9 levels significantly decreased. While the serum concentration of IL-6 increased during the follow-up period, regarding IL-10, no change was observed. In patients with 'low' baseline levels of C5b-9 (

AB - Background: Available data and our observations suggest that elevated levels of interleukin (IL)-6 and -10 and some complement parameters may be associated with a poor response to IFN alpha. We evaluated how baseline levels of C5b-9, IL-6, and IL-10 influence the outcome of IFN alpha treatment. Methods: Fifty-one patients with established chronic hepatitis C were enrolled and treated with IFN alpha-2b. Before and after a 12-week-IFN-treatment (3 MU or 5 MU tiw) serum levels of IL-6, IL-10, C5b-9 and RNA of hepatitis C virus (HCV) were assessed. Sera of 46 sex- and age-matched, healthy blood donors served as control. Results: While two-thirds of patients was considered 'responder', 14 patients had no significant decrease either in HCV RNA or in ALT levels. In the responder's group lower baseline levels of IL-6 and C5b-9 were found than those in the 'non-responder' group. As a result of IFN therapy HCV RNA and C5b-9 levels significantly decreased. While the serum concentration of IL-6 increased during the follow-up period, regarding IL-10, no change was observed. In patients with 'low' baseline levels of C5b-9 (

KW - C5b-9

KW - Chronic hepatitis C

KW - Interferon alpha-2b

KW - Interleukin-6

KW - Short-term response

UR - http://www.scopus.com/inward/record.url?scp=0033769241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033769241&partnerID=8YFLogxK

M3 - Article

C2 - 11099064

AN - SCOPUS:0033769241

VL - 35

SP - 1092

EP - 1096

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 10

ER -